NCT03945539View on ClinicalTrials.gov

A Study to Evaluate the Effect of Itraconazole on JNJ-56136379 in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

May 15, 2019

Primary Completion Date

October 4, 2019

Study Completion Date

October 4, 2019

Conditions
Healthy
Interventions
DRUG

JNJ-56136379

Participants will receive JNJ-56136379 orally on Day 1 in Treatment Period 1 and on Day 38 in Treatment Period 2.

DRUG

Itraconazole

Participants will receive 200 mg of itraconazole once daily orally for 21 days starting on Day 34.

Trial Locations (1)

2170

Clinical Pharmacology Unit, Merksem

All Listed Sponsors
lead

Janssen Sciences Ireland UC

INDUSTRY

NCT03945539 - A Study to Evaluate the Effect of Itraconazole on JNJ-56136379 in Healthy Adult Participants | Biotech Hunter | Biotech Hunter